Casalini P - Search Results

1

Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors.

Ménard S, Casalini P, Tomasic G, Pilotti S, Cascinelli N, Bufalino R, Perrone F, Longhi C, Rilke F, Colnaghi MI. Ménard S, et al. Among authors: casalini p. Breast Cancer Res Treat. 1999 May;55(2):169-77. doi: 10.1023/a:1006262324959. Breast Cancer Res Treat. 1999. PMID: 10481944

2

HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors.

Ménard S, Balsari A, Casalini P, Tagliabue E, Campiglio M, Bufalino R, Cascinelli N. Ménard S, et al. Among authors: casalini p. Clin Cancer Res. 2002 Feb;8(2):520-5. Clin Cancer Res. 2002. PMID: 11839672

3

Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas.

Ménard S, Tomasic G, Casalini P, Balsari A, Pilotti S, Cascinelli N, Salvadori B, Colnaghi MI, Rilke F. Ménard S, et al. Among authors: casalini p. Clin Cancer Res. 1997 May;3(5):817-9. Clin Cancer Res. 1997. PMID: 9815754

4

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

Ménard S, Valagussa P, Pilotti S, Gianni L, Biganzoli E, Boracchi P, Tomasic G, Casalini P, Marubini E, Colnaghi MI, Cascinelli N, Bonadonna G. Ménard S, et al. Among authors: casalini p. J Clin Oncol. 2001 Jan 15;19(2):329-35. doi: 10.1200/JCO.2001.19.2.329. J Clin Oncol. 2001. PMID: 11208823 Clinical Trial.

5

Role of hormonal risk factors in HER2-positive breast carcinomas.

Balsari A, Casalini P, Bufalino R, Berrino F, Ménard S. Balsari A, et al. Among authors: casalini p. Br J Cancer. 2003 Apr 7;88(7):1032-4. doi: 10.1038/sj.bjc.6600844. Br J Cancer. 2003. PMID: 12671699 Free PMC article.

6

Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study.

Campiglio M, Bufalino R, Sasso M, Ferri E, Casalini P, Adamo V, Fabi A, Aiello R, Riccardi F, Valle E, Scotti V, Tabaro G, Giuffrida D, Tarenzi E, Bologna A, Mustacchi G, Bianchi F, Balsari A, Ménard S, Tagliabue E. Campiglio M, et al. Among authors: casalini p. Breast Cancer Res Treat. 2013 Aug;141(1):101-10. doi: 10.1007/s10549-013-2658-z. Epub 2013 Aug 13. Breast Cancer Res Treat. 2013. PMID: 23942848 Free PMC article.

7

SEL1L expression decreases breast tumor cell aggressiveness in vivo and in vitro.

Orlandi R, Cattaneo M, Troglio F, Casalini P, Ronchini C, Ménard S, Biunno I. Orlandi R, et al. Among authors: casalini p. Cancer Res. 2002 Jan 15;62(2):567-74. Cancer Res. 2002. PMID: 11809711

8

HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.

Moliterni A, Ménard S, Valagussa P, Biganzoli E, Boracchi P, Balsari A, Casalini P, Tomasic G, Marubini E, Pilotti S, Bonadonna G. Moliterni A, et al. Among authors: casalini p. J Clin Oncol. 2003 Feb 1;21(3):458-62. doi: 10.1200/JCO.2003.04.021. J Clin Oncol. 2003. PMID: 12560435 Clinical Trial.

9

Two distinct local relapse subtypes in invasive breast cancer: effect on their prognostic impact.

Casalini P, Carcangiu ML, Tammi R, Auvinen P, Kosma VM, Valagussa P, Greco M, Balsari A, Ménard S, Tagliabue E. Casalini P, et al. Clin Cancer Res. 2008 Jan 1;14(1):25-31. doi: 10.1158/1078-0432.CCR-07-0450. Clin Cancer Res. 2008. PMID: 18172248

10

microRNA-205 regulates HER3 in human breast cancer.

Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Ménard S, Croce CM, Tagliabue E. Iorio MV, et al. Among authors: casalini p. Cancer Res. 2009 Mar 15;69(6):2195-200. doi: 10.1158/0008-5472.CAN-08-2920. Epub 2009 Mar 10. Cancer Res. 2009. PMID: 19276373

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

87 results

Search Page